[1]赵志勇,张婧,曹云太,等.基于MRI T1增强影像的影像组学模型预测较低级别胶质瘤IDH基因型的价值[J].中国临床神经外科杂志,2023,28(03):145-149.[doi:10.13798/j.issn.1009-153X.2023.03.001]
　ZHAO Zhi-yong,ZHANG Jing,CAO Yun-tai,et al.Prediction of radiomics model for IDH genotype in lower grade gliomas based on T1-weighted contrast-enhanced MRI[J].,2023,28(03):145-149.[doi:10.13798/j.issn.1009-153X.2023.03.001]
点击复制

基于MRI T1增强影像的影像组学模型预测较低级别胶质瘤IDH基因型的价值()
分享到：

《中国临床神经外科杂志》[ISSN:1009-153X/CN:42-1603/TN]

卷:
28
期数:
2023年03期
页码:
145-149
栏目:
论著
出版日期:
2023-03-31

文章信息/Info

Title:
Prediction of radiomics model for IDH genotype in lower grade gliomas based on T1-weighted contrast-enhanced MRI
文章编号:
1009-153X（2023）03-0145-05
作者:
赵志勇; 张婧; 曹云太; 张国晋; 孙建清; 李昇霖; 周俊林
730030兰州，兰州大学第二医院神经外科（赵志勇），放射科（李昇霖、周俊林）；276000广东珠海，遵义医科大学第五附属（珠海）医院医学影像中心（张婧）；810001西宁，青海大学附属医院医学影像中心（曹云太）；610020成都，四川省医学科学院/四川省人民医院放射科（张国晋）；201800上海，上海联影中央研究院（孙建清）
Author(s):
ZHAO Zhi-yong1;  ZHANG Jing2;  CAO Yun-tai3;  ZHANG Guo-jin4;  SUN Jian-qing5;  LI Sheng-lin6;  ZHOU Jun-lin6
1.Department of Neurosurgery, Lanzhou University Second Hospital, Lanzhou 730030, China; 2.Medical Imaging Center, The Fifth Affiliated (Zhuhai) Hospital of Zunyi Medical University, Zhuhai 276000, China; 3.Medical Imaging Center, Qinghai University Affiliated Hospital, Xining 810001, China; 4.Medical Imaging Center, Sichuan Academy of Medical Sciences, Sichuan Provincial People's Hospital, Chengdu 610020, China; 5.United Imaging Medical Technology Co., Ltd., Shanghai 201800, China; 6......
关键词:
脑胶质瘤; WHO分级Ⅱ级弥漫性胶质瘤; 间变型胶质瘤; 异柠檬酸酸脱氢酶; 基因突变; 影像组学; 预测
Keywords:
Glioma;  Lower grade gliomas;  Iso-citrate dehydrogenase;  T1-weighted contrast-enhanced MRI;  Radiomics;  Prediction
分类号:
A
DOI:
10.13798/j.issn.1009-153X.2023.03.001
文献标志码:
R739.41
摘要:
目的 探讨基于MRI T1增强影像的影像组学预测较低级别胶质瘤（LerGG；包括WHO分级Ⅱ级弥漫性胶质瘤和间变型胶质瘤）异柠檬酸酸脱氢酶（IDH）基因型的价值。方法 回顾性分析2017年1月至2020年6月手术切除并经术后病理证实的170例LerGG胶质瘤的临床资料和影像学资料，根据术前MRI T1增强影像，应用影像组学方法构建影像组学预测模型。结果 170例中，WHO分级Ⅱ级例60例，Ⅲ级110例。从MRI T1增强影像的感兴趣区中共提取了1 595个影像组学特征，降维分析后筛选5个影像组学标签，并构建预测模型，验证集和训练集分析显示模型预测IDH突变的曲线下面积分别为0.84、0.82，准确度分别为79%、80%，敏感度分别为81%、88%，特异度分别为75%、66%。结论 基于MRI T1增强影像的影像组学模型对WHO分级Ⅱ~Ⅲ级胶质瘤的IDH型具有较好的预测能力。
Abstract:
Objective To investigate the value of radiomics model based on T1-weighted contrast-enhanced MRI for predicting iso-citrate dehydrogenase (IDH) gene genotype in lower grade gliomas (LerGG; including WHO grade Ⅱ diffuse gliomas and intermediate-grade gliomas). Methods The clinical and imaging data of 170 patients with LerGG who were surgically resected from January 2017 to June 2020 and confirmed by postoperative pathological examination were retrospectively analyzed. The prediction model was established using radiomics methods based on the preoperative T1-weighted contrast-enhanced MRI. Results Of 170 patients with gliomas, 60 patients had grade Ⅱ gliomas and 110 patients had grade Ⅲ gliomas. A total of 1 595 radiomics features were extracted from the regions of interest of preoperative T1-weighted contrast-enhanced MRI. After dimension reduction analysis, 5 radiomics tags were screened out, and the prediction model of IDH mutation was constructed. The verification and training sets analyses showed that the area under the curve of the model to predict IDH mutation was 0.84 and 0.82, respectively; the accuracy was 79% and 80%, respectively; the sensitivity was 81% and 88%, respectively; the specificity was 75% and 66%, respectively. Conclusions The radiomics model based on T1-weighted contrast-enhanced MRI has a certain value to predict IDH genotype of patients with LerGG.

参考文献/References:

[1]Cancer Genome Atlas Research Network, Brat DJ, Verhaak RG, et al. Comprehensive, integrative genomic analysis of diffuse lower-grade gliomas [J]. N Engl J Med, 2015, 372(26): 2481-2498.
[2]杜　伟，陈义兵，魏新亭，等. 2016版《WHO中枢神经系统肿瘤分类》更新解读[J]. 中华神经外科杂志，2016，32（11）：1095-1098.
[3]Parsons DW, Jones S, Zhang X, et al. An integrated genomic analysis of human glioblastoma multiforme [J]. Science, 2008, 321(5897): 1807-1812.
[4]Bush NA, Butowski N. The effect of molecular diagnostics on the treatment of glioma [J]. Curr Oncol Rep, 2017, 19(4): 26.
[5]Olar A, Wani KM, Alfaro-Munoz KD, et al. IDH mutation status and role of WHO grade and mitotic index in overall survival in grade II-III diffuse gliomas [J]. Acta Neuropathol, 2015, 129(4): 585-596.
[6]Beiko J, Suki D, Hess KR, et al. IDH1 mutant malignant astrocytomas are more amenable to surgical resection and have a survival benefit associated with maximal surgical resection [J]. Neuro Oncol, 2014, 16(1): 81-91.
[7]赵　焕，白　岩，王梅云. 多模态磁共振成像技术在脑胶质瘤基因分型及预后评估中的研究进展[J]. 磁共振成像，2021，12（9）：98-102.
[8]Lu CF, Hsu FT, Hsieh KL, et al. Machine learning-based radiomics for molecular subtyping of gliomas [J]. Clin Cancer res, 2018, 24(18): 4429-4436.
[9]Ditmer A, Zhang B, Shujaat T, et al. Diagnostic accuracy of MRI texture analysis for grading gliomas [J]. J Neurooncol,2018, 140(3): 583-589.
[10]Qian Z, Li Y, Wang Y, et al. Differentiation of glioblastoma from solitary brain metastases using radiomic machine-learning classifiers [J]. Cancer Lett, 2019, 451: 128-135.
[11]Mouraviev A, Detsky J, Sahgal A, et al. Use of radiomics for the prediction of local control of brain metastases after stereotactic radiosurgery [J]. Neuro Oncol, 2020, 22(6): 797-805.
[12]Hyare H, Rice L, Thust S, et al. Modelling MR and clinical features in grade II/III astrocytomas to predict IDH mutation status [J]. Eur J Radiol, 2019, 114: 120-127.
[13]Maynard J, Okuchi S, Wastling S, et al. World Health Organization grade II/III glioma molecular status: prediction by MRI morphologic features and apparent diffusion coefficient [J]. Radiology, 2020, 296(1): 111-121.
[14]Compes P, Tabouret E, Etcheverry A, et al. Neuro-radiological characteristics of adult diffuse grade II and III insular gliomas classified according to WHO 2016 [J]. Neuro-oncology, 2019, 142(3): 511-520.
[15]Yu J, Shi Z, Lian Y, et al. Noninvasive IDH1 mutation estimation based on a quantitative radiomics approach for grade II glioma [J]. Eur Radiol, 2017, 27(8): 3509-3522.
[16]Liu X, Li Y, Li S, et al. Mutation-specific radiomic signature in lower-grade gliomas [J]. Aging (Albany NY), 2019, 11(2): 673-696.
[17]Kim M, Jung SY, Park JE, et al. Diffusion-and perfusion-weighted MRI radiomics model may predict isocitrate dehydrogenase (IDH) mutation and tumor aggressiveness in diffuse lower grade glioma [J]. Eur Radiol, 2020, 30(4): 2142-2151.
[18]Lambin P, Leijenaar RTH, Deist TM, et al. Radiomics: the bridge between medical imaging and personalized medicine [J]. Nat Rev Clin Oncol, 2017, 14(12): 749-762.
[19]Gore S, Chougule T, Jagtap J, et al. A review of radiomics and deep predictive modeling in glioma characterization [J]. Acad Radiol, 2021, 28(11): 1599-1621.
[20]王天达，席海蛟，袁　涛，等. 较低级别胶质瘤相关基因表型的形态与功能MR研究进展[J]. 临床放射学杂志，2021，40（10）：2037-2041.

相似文献/References:

[1]付　锴　江普查　宫　睿　王　伟.表达VASH1基因的人脑胶质瘤U-87MG细胞对化疗药物敏感性的变化[J].中国临床神经外科杂志,2016,(01):34.[doi:10.13798/j.issn.1009-153X.2016.01.012]
　FU Kai,JIANG Pu-cha,GONG Rui,et al.Effect of lentiviral vector-mediated VASH1 gene on chemosensitivity of human glioma U-87MG cells[J].,2016,(03):34.[doi:10.13798/j.issn.1009-153X.2016.01.012]
[2]崔焕喜,柳　琛.多模态MRI、神经导航和超声在脑胶质瘤术中的应用[J].中国临床神经外科杂志,2016,(11):721.[doi:10.13798/j.issn.1009-153X.2016.11.027]
[3]闫　珊　徐善才.多学科护理照顾模式对脑胶质瘤术后病人自我护理能力的影响[J].中国临床神经外科杂志,2017,(05):352.[doi:10.13798/j.issn.1009-153X.2017.05.026]
　YAN Shan,XU Shan-cai..Effects of multi-subjects nursing care model on self-care ability in patients with brain glioma after operation[J].,2017,(03):352.[doi:10.13798/j.issn.1009-153X.2017.05.026]
[4]罗似亮　夏之柏.脑胶质瘤病人脑脊液Midkine表达的临床意义[J].中国临床神经外科杂志,2017,(06):416.[doi:10.13798/j.issn.1009-153X.2017.06.017]
　LUO Si-liang,XIA Zhi-bo..Clinical meanings of midkine expression in cerebrospinal fluid of patients with gliomas[J].,2017,(03):416.[doi:10.13798/j.issn.1009-153X.2017.06.017]
[5]呼铁民　褚会松　田　甜　王昆鹏　杨国军　杨立军　王维兴.脑胶质瘤ADAM17与EGFR的表达及临床意义[J].中国临床神经外科杂志,2017,(08):557.[doi:10.13798/j.issn.1009-153X.2017.08.012]
　HU Tie-min,CHU Hui-song,TIAN Tian,et al.Expressions of ADAM17 and EGFR in gliomas tissues and their clinical meanings[J].,2017,(03):557.[doi:10.13798/j.issn.1009-153X.2017.08.012]
[6]汪超甲 综述　王　辉 审校.脑胶质瘤化疗现状及耐药机制的研究进展[J].中国临床神经外科杂志,2017,(11):791.[doi:10.13798/j.issn.1009-153X.2017.11.023]
[7]高剑峰　姚庆和　李晓辉　龙宇波　陈振波.脑胶质瘤miR-9、PPARγ表达水平及临床意义[J].中国临床神经外科杂志,2018,(01):17.[doi:10.13798/j.issn.1009-153X.2018.01.006]
　GAO Jian-feng,YAO Qing-he,LI Xiao-hui,et al.Expressions of miR-9 and PPARγ in human brain gliomas and their clinical meanings[J].,2018,(03):17.[doi:10.13798/j.issn.1009-153X.2018.01.006]
[8]刘　靖　吴立权　黄书岚.聚焦解决模式对脑胶质瘤术后病人自我管理效能感及生命意义的影响[J].中国临床神经外科杂志,2018,(03):208.[doi:10.13798/j.issn.1009-153X.2018.03.025]
　LIU Jing,WU Li-quan,HUANG Shu-lan..Effects of solution focused intervention on self-management efficacy and meanings of life in the patients with gliomas after surgery[J].,2018,(03):208.[doi:10.13798/j.issn.1009-153X.2018.03.025]
[9]刘　炎　杭春华.脑胶质瘤卒中误诊为脑动静脉畸形并出血1例[J].中国临床神经外科杂志,2018,(06):448.[doi:10.13798/j.issn.1009-153X.2018.06.025]
[10]刘东明　胡新华　刘　永　陈　玖　刘宏毅.脑胶质瘤病人静息态默认模式网络研究进展[J].中国临床神经外科杂志,2018,(12):821.[doi:10.13798/j.issn.1009-153X.2018.12.022]

备注/Memo

备注/Memo:
（2022-10-16收稿，2022-12-26修回）
基金项目：甘肃省卫生健康行业科研计划项目（GSWSKY2021-006）
通讯作者：周俊林，E-mail：ery_zhoujl@lzu.edu.cn
更新日期/Last Update: 2022-04-30